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Abstract
Introduction: To provide an overview of drug use in palliative care worldwide and to identify the most 
commonly used medicines in palliative care settings.
Methods: Quasi–systematic review. Search strategy: Medline/PubMed, Embase, SCOPUS and Google 
Scholar were searched utilizing the selected MeSH terms: palliative care, hospice, drug utilization, and 
prescription patterns.
Results: Overall, it is apparent that there is a significant lack of published literature outlining drug usage in 
palliative care settings. Twelve sources of information were reviewed from 9 different countries including 
Austria (n = 1), Brazil (n = 1), Canada (n = 1), Germany (n = 1), Italy (n = 2), Netherlands (n = 2), Norway 
(n = 1), Switzerland (n = 1) and USA (n = 3), as well as a multinational study comparing 11 European co-
untries. Medication use between countries was similar. The most commonly prescribed classes of medicines 
included non-opioid analgesics, opioids, laxatives, sedatives and antipsychotics and the most commonly 
prescribed individual drugs comprised morphine, haloperidol, laxatives and paracetamol.
Conclusions: The literature identifies that there is insufficient evidence to describe and compare what drugs 
are currently used in palliative care settings worldwide. This is attributed to the lack of recently published 
articles leading to a large gap in knowledge in understanding drug utilization practices in palliative care. 
Further research is required to address these gaps in knowledge, and identify medication management issues 
in palliative care and determining whether there are significant differences in drug management practices. 
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Introduction
The World Health Organization (WHO) estimates 
that as many as 40 million people each year are in 
need of palliative care [1]. Within this setting, timely 
access to appropriate medical interventions as well as 
social, psychological, and spiritual support is essential 
[2]. However, it is reported that one of the largest 
inequalities in global health relates to the lack of 
access to symptom relief during palliative care [1]. 
From a medical perspective, the core principles of 
palliative care focus on the appropriate assessment, 
prevention and management of symptoms, including 
but not limited to pain, nausea, fatigue, and delirium 
[2, 3]. Therefore, medications play a particularly in-
tegral role in ensuring the comfort of this group of 
patients. Specifically, an individualised drug regimen is 
considered imperative in the care of palliative patients, 
and as such, the subsequent use of pharmacotherapy 
within this setting is unique [4]. Dosing strategies, for-
mulations and routes of administration differ to those 
applied within other hospital units, in accordance with 
each patients needs, and often require unlicensed 
or off-label prescribing [5]. Kwon et al. highlighted 
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that 35% of prescriptions in an acute palliative unit 
in the USA were off-label, with the most common 
including haloperidol, dexamethasone and morphine 
[6]. Examples of off-label prescribing included the use 
of anticonvulsants for pain relief or opioids to treat 
dyspnoea [5]. Due to the importance of ensuring 
the dignity of patients with advanced diseases, the 
appropriate and quality use of medicines in palliative 
care is vital. Medication errors, misuse or interactions 
may cause unnecessary pain and discomfort, and cau-
se distress to the patient and also to family members 
and friends. With a reported average of 15.7 drugs 
prescribed per patient, there is a need to implement 
a high–quality, safe and rational medicine use process 
for these patients to ensure optimal levels of comfort 
and symptom relief [3]. 
In order to bridge the gap across palliative care 
settings internationally, WHO established a list of es-
sential medicines in palliative care, intended to guide 
countries to develop their own medication policies 
and formularies [7–9]. There have also been studies 
performed in Australia and Sweden that have sought 
to create smaller essential medicines list that is suita-
ble for their respective nations [10–12]. However, the 
medicines used in palliative care settings, including 
hospices, hospital units or home care settings, may 
vary significantly according to their availability and 
accessibility in each country, as well as the interna-
tional/national regulations and rules of each setting. 
For example, Cleary highlighted that despite holding 
a position on the essential medicines list, morphine 
was not readily available in appropriate dosage forms 
in East Africa and only became accessible in Bangla-
desh in 2014 [13]. Alternatively, efforts have been 
made in Australia to create the first-ever section in the 
Pharmaceutical Benefits Scheme for a specific group 
of patients with the inclusion of a palliative section 
that improves access to affordable palliative drugs 
outside of the hospital setting including morphine, 
clonazepam, methadone and hyoscine butylbromide 
[14]. Therefore, there may be inconsistencies relating 
to the patterns of prescribing and drug utilization 
within different palliative care settings internationally. 
There has been limited number of studies dedicated to 
drug utilization reviews, which identify and define the 
types of drugs used in palliative care settings in each 
country. Often studies are dedicated to one class of 
medicines, i.e. opioids, and do not take into account 
the entire pharmacotherapeutic spectrum [15, 16]. 
It is important to understand the differences in drug 
use between countries to highlight any inequalities 
in medication management and to be able to better 
tailor strategies to improve palliative care provided 
to patients on a global scale. The purpose of this 
review was to provide an overview of medicine use 
in palliative care worldwide and to identify the most 
commonly used drugs in palliative care settings.
Methods
A quasi-systematic review was undertaken to iden-
tify relevant publications relating to drug utilization 
and prescription patterns in palliative care. A com-
prehensive search was performed using the MeSH 
terms palliative care, hospice, drug utilization, and 
prescription patterns. Inclusion criteria for the search-
es restricted the content to drug utilization studies 
that provided information on drug use patterns, 
prescriptions patterns or drug consumption and were 
written in the English language. The electronic data-
bases searched to identify relevant articles included: 
MEDLINE, EMBASE, Scopus and Google Scholar. A date 
limit was applied so that only articles published from 
the year 2000–2018, were included. Articles were 
excluded if they only evaluated the use of a single 
class of medications i.e. opioids. All full–text articles 
were retrieved. Manual bibliographic searches were 
also performed to identify additional articles that were 
not found in the electronic searches. All articles were 
initially screened for inclusion in the review based on 
the title, then abstract and full text article as necessary. 
Results
A total of 12 studies were found to meet the 
inclusion criteria and were included in the review. 
(Table 1) Studies were conducted in nine different 
countries, with one study analysing data from 11 dif-
ferent European countries – Austria (n = 1) [17], 
Brazil (n = 1)(18), Canada (n = 1) [19], Germany 
(n = 1) (17), Italy (n = 2) [20, 21], Netherlands 
(n = 2) [4, 22], Norway (n = 1) [23], Switzerland 
(n = 1) [17] and USA (n = 3) [3, 24, 25]. The mul-
tinational study reported on medication use in 
Norway, Italy, Germany, the UK, Iceland, Sweden, 
Switzerland, Lithuania, Denmark, Finland and Greece 
[26]. It is apparent that there is a significant lack of 
published literature outlining drug usage in palliative 
care settings. However, three quarters (9/12) of the 
articles reviewed were published in the last 9 years 
(date range: 2011–2016) [3, 4, 18, 21–26]. The 
majority of studies used a retrospective means of 
data extraction [3, 4, 19–21, 23–26] and ranged in 
duration from 3 months to 5 years. As a result, the 
number of participants enrolled in the studies varied 
significantly, from 87 to 4252 patients. This may be 
also attributed to the number of settings included 
in each study, with some articles exploring large 
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Table 1. Studies included in the review
Author Year Country Palliative care 
setting
Duration 
of study
Number 
of partici-
pants
Study design
Dwyer et al. 
[24]
2015 USA Hospice 6 months 2623 Retrospective cross-
sectional study
Fede et al.  
[18]
2011 Brazil 3 oncology clinics, 
and 1 chemothera-
py clinic
6 months 87 Prospective, cross-
sectional survey
Hui et al.  
[25]
2015 USA Acute palliative 
care unit
4 months 100 Retrospective chart 
review
Jansen et al. 
[23]
2014 Norway 3 Nursing homes 5 years 524 Historical cohort 
study
Kotlinska- 
-Lemieszek  
et al. [26]
2014 Norway, Italy, Germa-
ny, the UK, Iceland, 
Sweden, Switzerland, 
Lithuania, Denmark, 
Finland, Greece
Oncology wards, 
palliative care 
units/hospices, 
outpatient clinics, 
surgical wards
4 years 2282 Retrospective chart 
review
Masman  
et al. [4]
2015 The Netherlands Palliative care 
centre
1 year 208 Retrospective co-
hort study
Mercandante 
et al. [20]
2001 Italy Home palliative 
care program
2 years 128 Retrospective co-
hort study
Nauck  
et al. [17]
2004 Austria, Germany 
and Switzerland
Palliative care unit 3 months 1304 Prospective cohort 
study
Raijmakers  
et al. [21]
2013 Italy Hospital and ho-
spice units
3 years 195 Retrospective chart 
review
Riechelmann 
et al. [19]
2007 Canada Palliative care clinic 8 months 255 Retrospective cross 
– sectional study
Sera et al. [3] 2014 USA Hospice 1 year 4252 Retrospective 
review
Van Norden-
nen et al. [22]
2016 The Netherlands Inpatient palliative 
care facility
6 months 155 Observational, pro-
spective, multicen-
tre cohort study
databases or results of nationally representative 
sample surveys whereas others focussed on single 
palliative care units. 
The criteria for enrolling patients into studies were 
relatively consistent and based on patient admission 
into a palliative care setting. The most commonly 
reported reasons for admission included advanced 
cancer/malignancies and pain [3, 4, 17, 18, 22, 25, 
26]. The studies were based in different palliative care 
settings, including palliative care units in hospitals, 
nursing homes, home care and inpatient (stationary) 
hospices. Patients enrolled in studies mostly held 
diagnoses of cancer, dementia or heart disease/heart 
failure [17–19, 21–26]. Female patients comprised 
38–65% of participant samples [4, 18–23, 25, 26]. 
The mean age of patient groups ranged from 58–
77.5 years of age [3, 17, 18, 20–22, 25, 26]. The 
median duration of stay in palliative care for patients 
ranged from 8 to 103 days [3, 4, 22, 23, 25].
Commonly used drugs
Overall, 5 most commonly prescribed classes of 
medications were reported as being non-opioid anal-
gesics, opioids, laxatives, antipsychotics and sedati-
ves [3, 4, 17–26]. Fig. 1 presents an overview of the 
10 most commonly prescribed classes of medicines 
for palliative care patients. Within these classes of 
drugs, the most commonly prescribed individual me-
dicines included morphine, haloperidol, laxatives and 
paracetamol [3, 4, 17, 20, 21, 23]. Figure 2 presents 
an overview of 10 most commonly prescribed medi-
cations in palliative care settings. The most common 
route of administration was identified as subcutaneo-
us, followed by oral and transdermal [4, 21].
Overall, it is apparent that drug usage across coun-
tries is relatively consistent with little to no differences 
in the types of drugs prescribed (Table 2). However, 
Kotlinska-Lemieszek et. al. identified in a study of drug 
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Figure 1. Ten most commonly used classes of drugs prescribed in palliative care settings worldwide
use in palliative care settings across 11 European co-
untries that the use of non-opioid analgesics and 
corticosteroids differed between certain countries 
[26]. Corticosteroids were used in 33.6% of patients 
in Germany and the UK, however, were used in over 
70% of patients in Italy and Sweden. Furthermore, 
30.6% of patients in Italy were using non-opioids, in 
comparison to almost 70% of patients in Sweden and 
Switzerland [26]. 
Discussion
To our knowledge, this is the first review to provide 
an insight into medicines use in palliative care settings 
worldwide. The review presented both the therapeutic 
groups used in palliative care as well as individual 
drugs. Overall, it appears that the types of medicines 
used in palliative care settings on a global scale are 
similar, with high usage of non-opioid analgesics, 
opioids, sedatives and antipsychotics. As the majority 
of studies included in the review are from developed, 
European countries, this finding was anticipated. 
However, there is a significant lack of published liter-
ature outlining drug use in palliative care settings in 
general. Most studies are dedicated to single classes 
of medications i.e. opioids and do not explore the en-
tire range of pharmacotherapy utilized in this patient 
population. Overall, it is difficult to ascertain the true 
extent of drug utilization in palliative care settings 
in each country as relevant literature from Australia, 
Asia, South America and a large proportion of Africa 
and Europe was not available. 
Treatment of pain is a priority in palliative care 
as well as the management of dyspnea, delirium, 
anxiety, nausea, vomiting, constipation, and other 
symptoms. According to Franken et al. morphine, 
haloperidol and midazolam were identified as the 
three most commonly used drugs used in palliative 
care which was also indicated in our review [27]. 
When considering the application of pain relief, the 
review found that non-opioid analgesics including 
paracetamol, and opioids such as morphine and 
fentanyl were found to be used often in pallia-
tive care settings worldwide. It is unsurprising, that 
morphine, as a natural prototype of all opioids, was 
listed in most studies. Generally speaking, it, is used 
for pain management in the treatment of cancer, 
during palliative care typically via oral route with 
controlled-release formulations for the treatment of 
chronic pain, as well as in immediate-release solutions 
Palliative Medicine in Practice 2019, tom 13, nr 3
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Figure 2. Most commonly cited drugs used in palliative care settings worldwide
Table 2. Drug use by country
Country Most commonly used drugs cited in articles
Austria, Germany, Switzerland [17] Dipyrone, Morphine, Fentanyl
Brazil [18] Paracetamol, Dipyrone
Canada [19] Opioids, Laxatives, Corticosteroids
Italy [20, 21] Morphine, Ranitidine, Midazolam
The Netherlands [4, 22] Morphine, Midazolam, Haloperidol, Paracetamol, Fentanyl, Ma-
crogol
Norway [23] Morphine, Midazolam, Glycopyronium
USA [3, 24] Paracetamol, Lorazepam, Morphine, Haloperidol
Multinational study — Norway, Italy, Germany, 
UK, Iceland, Sweden, Switzerland, Lithuania, 
Denmark, Finland, Greece [26]
Opioids, Proton Pump Inhibitors, Laxatives
or tablets for the management of breakthrough pain 
episodes. Morphine is also used in the symptomatic 
management of dyspnoea. The findings also showed 
that fentanyl was commonly used, which may be 
due to its outstanding properties as a small molecule 
with lipophilicity, allowing the use of this opioid for 
the management of chronic pain in patches via the 
transdermal route.
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It is important to consider that the level of opioid 
consumption is closely related to the ease of access to 
opioids in each country. Duthey et al. conducted a survey 
determining the levels of opioid consumption on a global 
scale, and included countries that were analyzed in this 
review including Canada, Germany, Switzerland and the 
USA [28]. The levels of consumption were compared with 
the Adequacy of Consumption Measure (ACR) [28]. Inter-
estingly, non–European countries including Canada and 
the USA presented the highest levels of opioid consump-
tion, with the consumption of morphine equivalents per 
capita listed as 657.27 mg in Canada, and 481.99 mg in 
the USA, indicating ready access to opioids [28]. In Italy, 
the Netherlands and Norway the consumption of opi-
oids was estimated as being moderate (ACR 30–100%) 
[28]. Among these countries, Italy indicated the lowest 
levels of opioid consumption: 71.06 mg of morphine 
equivalents per capita and an ACM of 34.01%, however 
was still deemed satisfactory [28]. The study concluded 
that the analyzed countries did not experience obvious 
barriers to opioid access, which may then have a positive 
influence on pain treatment [28]. 
Haloperidol as a typical antipsychotic was also seen 
to be used in palliative care settings often. However, 
its use for delirium in palliative care patients is deba-
table. In a placebo-controlled randomized clinical trial, 
haloperidol was compared to risperidone (atypical 
antipsychotic) and to a placebo in the treatment of 
delirium in patients receiving palliative care [29]. Inte-
restingly, the study concluded that antipsychotic drugs 
are not useful in reducing the symptoms of delirium 
associated with distress in palliative patients [29]. The 
authors showed that behaviour, communication, and 
perceived symptoms of delirium were significantly 
greater in the group of patients treated with antipsy-
chotics (risperidone or haloperidol) [29]. However in 
contrast, a large meta-analysis (58 randomized con-
trolled trials, 9603 patients) indicated that haloperidol 
with the addition of lorazepam experienced the best 
response rate for the pharmacological treatment of 
delirium in general [30]. In practice, haloperidol is 
often recommended in combination with midazolam 
for refractory delirium in palliative care sedation [31]. 
This combination has been shown to be more effective 
in the treatment of agitation in palliative care patients 
than haloperidol alone [32]. Our findings highlighted 
that midazolam as an individual pharmacotherapy also 
rated highly amongst the most commonly used dru-
gs. It is indicated in palliative care patients for anxiety, 
agitation and as an anticonvulsant. Midazolam can be 
also used in the management of dyspnoea and hiccup. 
However, morphine and metoclopramide are regarded 
as being first choice therapies of the symptomatic 
treatment of dyspnoea and hiccup, respectively [33].
The findings of the review highlighted the number 
of drugs used in palliative care settings worldwide. 
There was a perceived difference between EU coun-
tries, where the number of medicines was approxi-
mately 5 per patient and the USA, where one study 
listed 10 different drugs for use in one patient. These 
differences may be attributed as being a consequence 
of the many guidelines available in the USA recom-
mending treatment for particular medical conditions, 
in most cases suggesting 2 or 3 drugs rather than mo-
notherapy to increase the efficacy of the treatment. 
However, from a perspective of palliative care there 
is limited to no appropriate evidence guiding the use 
of therapy in patients with many different coexisting 
symptoms [34]. As a result this leads to polypharma-
cy, defined as the use of more than 5 medications in 
a single patient at the same time [35]. Polypharmacy 
is a very common issue among palliative care patients 
because of the high prevalence of multiple conditions 
which may require pharmacological management. 
Often, the adverse effects of one medication results 
in the need for the addition of other drugs to manage 
the subsequent symptoms i.e. treatment with opioids 
often requires the addition of laxatives to prevent or 
treat opioid-induced constipation. It is important to 
note that polypharmacy can lead to many negative 
outcomes including the exacerbation of adverse ef-
fects and the potential to increase the incidence of 
drug drug interactions [36, 37]. According to the 
Unnecessary Drug Use Measure, (a tool evaluating 
the proper use of drugs according to their indication, 
efficacy and therapeutic duplication), there is a need 
to analyse, and if possible, decrease the number 
medicines prescribed for a single patient to minimise 
the possibility of inappropriate medications use [38].
Limitations of the review
The main limitation of this review is the lack of 
recently published literature outlining the prescription 
patterns of drugs used in palliative care settings, 
limiting the analysis that could be done and also the 
comparisons between countries. The findings may 
not be representative of palliative care settings in 
each country and should be interpreted with caution. 
However, this study can inform future research to 
capture a more comprehensive view of medication 
use in palliative care settings.  
Conclusions
Overall, medication use is similar in palliative care 
settings worldwide, with a strong emphasis on pain 
relief. However, the 12 articles reviewed in this paper 
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do not give a sufficient summary of medication use 
and may provide a biased insight into drug utilization. 
Given the diversity of practice, it is important to pro-
vide clear descriptions of prescription patterns within 
palliative care and compare drug utilization across 
different clinical settings and countries to identify 
whether there are any differences in practice. There 
is a need for future research to focus on canvassing 
a more comprehensive overview of drug use in pal-
liative care settings. 
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